[go: up one dir, main page]

WO2018222167A9 - Utilisation d'une préparation à base de plantes contenant de l'huile de lin dans le traitement de maladies du système cardiovasculaire - Google Patents

Utilisation d'une préparation à base de plantes contenant de l'huile de lin dans le traitement de maladies du système cardiovasculaire Download PDF

Info

Publication number
WO2018222167A9
WO2018222167A9 PCT/TR2018/050093 TR2018050093W WO2018222167A9 WO 2018222167 A9 WO2018222167 A9 WO 2018222167A9 TR 2018050093 W TR2018050093 W TR 2018050093W WO 2018222167 A9 WO2018222167 A9 WO 2018222167A9
Authority
WO
WIPO (PCT)
Prior art keywords
linseed oil
oil
treatment
herbal
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050093
Other languages
English (en)
Other versions
WO2018222167A3 (fr
WO2018222167A2 (fr
Inventor
Mevlüt Büyükhelvacigi̇l
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret AS
Original Assignee
Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret AS filed Critical Helvacizade Gida Ilac Kimya Sanayi Ve Ticaret AS
Publication of WO2018222167A2 publication Critical patent/WO2018222167A2/fr
Publication of WO2018222167A3 publication Critical patent/WO2018222167A3/fr
Publication of WO2018222167A9 publication Critical patent/WO2018222167A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to use of an herbal formulation containing linseed oil (Oleum Lini) in the drug industry in the chemical industry.
  • the invention relates to use of an herbal formulation that is prepared with linseed oil being rich in alpha-linolenic acid which is an herbal fatty acid containing Omega 3; that is in the form of a capsule having an antioxidant property, in the treatment of cardiovascular system diseases.
  • Omega 3 is an essential fatty acid, it is a fatty acid that should be taken from outside to maintain the organism's life as other essential fatty acids and that cannot be synthesised in body. This essential fatty acid should be taken by means of nutrition and supplements into body.
  • ALA that is an herbal fatty acid containing Omega 3 taken from outside into organism can be used as an herbal Omega 3 (ALA) source in those, particularly in vegetarians who cannot use fish oil and functions as an adjuvant in regulating some blood lipid (fat) levels, treatment of chronic constipation, treatment of cardiovascular system disease and mild gastrointestinal discomfort.
  • the invention mentions a shower foam prepared with various herbal materials including linseed that is natural and providing vitality and softness to skin.
  • the application numbered CN105560646 mentions an herbal mixture comprising nanking cherry, tamarind, banana, dragon's tongue leaf, carageen, Russian bochniakia plant, Japanese dok roots, Nepal dok roots, radix Scrophulariae, radix lithospemi, coffee bean, senna, unripe Inula, orange, pakchoi plantlets, alopecia, senna and peach flowers as well as linseed so as to treat the symptoms such as constipation, irregular bowel movements, hard stool and pellet-like dry stool.
  • Linseed oil causes serum total cholesterol levels to decrease by 15 percent.
  • Use of linseed oil containing highly ALA decreases serum total cholesterol, LDL (low density lipoprotein) levels on people with hyperlipidemia. Further, LDL cholesterol levels are decreased on postmenopausal women.
  • SDG secoisolariciresional diglucoside
  • Another object of the invention is to provide a formulation containing no chemical substances, and being totally natural and herbal. No heat or chemical treatment is carried out even when the linseed oil used in the content of the formulation is obtained. Thus, active substances, nutritional values, vitamin and minerals in the plant are directly infused into the product without losing them.
  • Another object of the invention is to ensure to minimise the side effects badly affecting the human health by means of the content formed without chemicals.
  • the side effects affecting only gastro-entero system such as nausea, vomit, diarrhea resulting from the use of totally natural and herbal products is rarely observed.
  • Further object of the invention is to provide ease of use in terms of patient compliance through the fact that the formed formulation is in the form of capsule. Furthermore, it is advantageous in administrating the dosing in said indications by means of the formed capsule form.
  • Linseed there are oil and lignans being rich in omega-3(ALA) in the linseed. Linseed among the oils obtained through seeds comes into prominence because it has highly olinolenic acid (ALA, 18:3n-3) and lignans. Linseed comprises oil rate of 35-45 percent whose ALA rate is varying between 45-52 percent thereof. ALA is classified as Omega 3 group of fatty acids.
  • Linseed oil causes serum total cholesterol levels to decrease by 15 percent.
  • Use of linseed oil containing highly ALA decreases serum total cholesterol, LDL (low density lipoprotein) levels on people with hyperlipidemia. Further, LDL cholesterol levels are decreased on postmenopausal women.
  • SDG secoisolariciresional diglucoside
  • Linseed oil exhibits antioxidant effects due to ALA therein. Furthermore, ALA has suppressor effects on interleukin, TNF (Tumor necrosis factor), leukotriene B4 and polymorphonuclear leukocytes. These facts can explain the effects of linseed oil that can inhibit the development of inflammation. It is known that linseed oil can increase calcium absorption. Along with the effect, it has supportive effects on bone health.
  • the linseed oil not only is a good nutritional source but also improve bowel movement in adults due to fibrous structure therein. Defecation frequency and continuity are regulated on those who uses the linseed oil. Therefore, the formulation can be used as adjuvant to the treatment of chronic constipation and mild gastrointestinal problems.
  • the linseed oil is important for adults who cannot use fish oil, particularly vegetarians within the scope of the fact that it is supportive in terms of herbal Omega 3. Content of capsule formulation:
  • Linseed oil as active substance and dl otocopherol, dl otocopheril acetate, glycerine, purified water and gelatine as inactive substances are employed in the formulation, dl otocopherol and otocopheril acetate serve as preservative substance.
  • Dl otocopherol and dl otocopheril acetate are added into the formulation in the ratio of ppm.
  • Bovine gelatine is used so as to maintain the integrity of content.
  • other animal-originated and herbal gelatines can be used.
  • the gelatine is prepared in the gelatine preparing unit so as to maintain the integrity of capsule while carrying out these processes.
  • capsules in desired dosages are prepared by means of sending it to capsule producing unit. Said capsules are gelatine capsules. After prepared the capsule, drying process is carried out. Dried capsules are packaged.
  • the capsule is rich in alpha-linolenic acid (ALA) being Omega 3 that is herbal. It is adjuvant to the treatment of patients with chronic constipation. Further, it is adjuvant to the treatment of cardio-vascular system diseases, regulating some blood lipid (fat) levels and mild gastrointestinal problems.
  • ALA alpha-linolenic acid
  • the capsule can be used as an herbal Omega 3 (ALA) source on those who cannot use fish oil, particularly on vegetarians.
  • Dosing administration frequency and period As long as doctor recommends otherwise; the capsules are taken orally as 2-4 capsules (1250-2500 mg/day at dose) per day by adults (aged 18 and older). The capsule can be taken as 1 -2 capsules (625- 1250 mg/day) by children over 12 years of age.
  • the capsules should be swallowed along with enough water, preferably on a full stomach without crushing and chewing them in mouth.
  • Each capsule contains 0, 161 g of glycerine. It is not expected to appear any side effects resulting from the glycerine at this ratio.
  • the capsule should be carefully used in the course of the treatment of hormone-related tumors due to its oestrogen ic effect.
  • Pregnancy period The capsule should not be used because no study related to this matter has been performed.
  • Lactation period The capsule should not be used in the course of lactation because its safety in the lactation is not proven.
  • Gastrointestinal Diseases Commonly meteorism and rarely hypersensitivity reactions similar to anaphylaxis can be observed along with the use of capsule. Further, nausea, vomit and diarrhea can be observed, however its frequency is not known. Apart from these, no undesirable effect is reported. Overdose:
  • shelf life of the product is determined as 2 years.
  • This product has been licensed and approved for pharmacodynamic properties of a Traditional Herbal Medicine product by a health authority such as the Ministry of Health.
  • This product has been approved by a health authority, such as the Ministry of Health, by licensing the SPI (Short Product Information-Prospectus) and Ul (Use Instructions) of a Traditional Herbal Medical product.
  • This product has been approved by a health authority such as the Ministry of Health by standardizing and licensing the usage and dosing of a Traditional Herbal Medicinal product.
  • the traditional herbal medical product licensed by the Ministry of Health, dosing of which is stated in writing in compliance with the clinical studies has been officialised by obtaining the approval of health authorities and presented to the service of world medicine.
  • Flaxseed reduces total and LDL cholesterol concentrations in Native American postmenopausal women. J Womens Health (Larchmt) 2008; 17(3): 355-66.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dans l'industrie pharmaceutique, l'invention concerne l'utilisation d'une préparation à base de plantes contenant de l'huile de lin riche en acide alpha-linolénique (ALA) qui est un acide gras oméga 3 à base de plantes dans le traitement de maladies du système cardiovasculaire. Ladite préparation à base de plantes comprend de l'huile de lin, du dl-α-tocophérol, du dl-α-tocophéryl acétate, de la glycérine, de l'eau purifiée et de la gélatine maintenant l'intégrité et la formation du contenu.
PCT/TR2018/050093 2017-03-10 2018-03-09 Utilisation d'une préparation à base de plantes contenant de l'huile de lin dans le traitement de maladies du système cardiovasculaire Ceased WO2018222167A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/03736 2017-03-10
TR2017/03736A TR201703736A2 (tr) 2017-03-10 2017-03-10 Keten tohumu yaği i̇çeren bi̇r bi̇tki̇sel formülasyonun kalp damar si̇stemi̇ hastaliklarinin tedavi̇si̇nde kullanimi

Publications (3)

Publication Number Publication Date
WO2018222167A2 WO2018222167A2 (fr) 2018-12-06
WO2018222167A3 WO2018222167A3 (fr) 2019-01-17
WO2018222167A9 true WO2018222167A9 (fr) 2019-04-11

Family

ID=64456358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050093 Ceased WO2018222167A2 (fr) 2017-03-10 2018-03-09 Utilisation d'une préparation à base de plantes contenant de l'huile de lin dans le traitement de maladies du système cardiovasculaire

Country Status (2)

Country Link
TR (1) TR201703736A2 (fr)
WO (1) WO2018222167A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103966B (zh) * 2006-07-14 2010-11-03 上海展望科技有限公司 ω-3脂肪酸-大蒜油胶囊及其制造方法
CN101919457A (zh) * 2010-09-01 2010-12-22 吴桂荣 调和胡麻籽油及应用
CN104288345B (zh) * 2013-07-15 2018-08-24 湘北威尔曼制药股份有限公司 一种辅助降血脂的中药组合物及其制备方法

Also Published As

Publication number Publication date
WO2018222167A3 (fr) 2019-01-17
WO2018222167A2 (fr) 2018-12-06
TR201703736A2 (tr) 2017-07-21

Similar Documents

Publication Publication Date Title
CN105053276B (zh) 无蔗糖功能性牡丹籽油粉末油脂的制备方法
Oguntibeju et al. Red palm oil: nutritional, physiological and therapeutic roles in improving human wellbeing and quality of life
EP2708147B1 (fr) Procédés pour augmenter la fonctionnalité du cerveau utilisant du 2-fucosyllactose
KR102186932B1 (ko) 식이 지방산 수요를 공급하기 위한 방법들, 조성물들 및 디바이스들
CN105104584B (zh) 含活性肽的牡丹籽油粉末油脂的制备方法
CN107441217B (zh) 一种富含α-亚麻酸的口服乳剂及其制备方法
Nogueira-de-Almeida et al. Impact of soy consumption on human health: Integrative review
US10653655B2 (en) Composition for preventing or improving peripheral neuropathy
Srivastava et al. Nutraceuticals: A review
Maurya Bioactive Compounds in Dry Fruit Oils: Mechanisms of Action and Therapeutic Insights
AU2014202925B2 (en) Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders
WO2018222167A9 (fr) Utilisation d'une préparation à base de plantes contenant de l'huile de lin dans le traitement de maladies du système cardiovasculaire
WO2018226190A9 (fr) Utilisation d'une préparation à base de plantes contenant de l'huile de lin dans le traitement de la constipation chronique
WO2018226191A9 (fr) Utilisation de formulation à base de plantes contenant de l'huile de lin dans le traitement de troubles (du système gastro-intestinal) gastro-intestinaux légers
WO2018222166A9 (fr) Utilisation d'une préparation à base de plantes, contenant de l'huile de lin, dans le traitement de régulation des taux de lipides (graisse) dans le sang
Šunderić et al. Is there something fishy about fish oil?
WO2018226192A9 (fr) Utilisation d'une préparation à base d'herbes contenant de l'huile de lin pour ceux qui ne peuvent pas utiliser de l'huile de poisson, en particulier pour les végétariens, en tant que source végétale d'oméga 3 (ala)
RU2194522C1 (ru) Лечебно-профилактический комплекс
JP2008546845A (ja) 心臓血管疾患の治療のためのポリメトキシフラボン類およびトコトリエノール類のバイオアベイラビリティーを改善する組成物
US8758840B2 (en) Method of treating areas of osteoarthritis in animals and human beings with milkweed seed oil
WO2018222164A2 (fr) Utilisation d'une préparation à base d'herbes contenant de l'huile de pépins de courge dans le traitement de la hbp
Dian et al. Palm-based vitamin E (Tocotrienol-Rich Fraction) has excellent stability in chewable tablet after one-year of storage at ambient temperature
JPS58162273A (ja) キビ抽出物を主体とした健康食品
Winata et al. A NARRATIVE REVIEW OF KNOWN PLANTS WHICH HAVE POTENTIAL BENEFITS AS NATURAL GALACTAGOGUES IN INDONESIA.
Suryawanshi et al. REVIEW ON: NUTRACEUTICALS AND ITS IMPACT ON HEALTHCARE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18810355

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18810355

Country of ref document: EP

Kind code of ref document: A2